Inorganic Nanomedicines Flashcards
what are 2 properties of inorganic nanoparticles
between 1-100 nm
shows different properties to bulk
what 4 properties do inorganic nanoparticles have
optical
electrical
photothermal
magnetic
why are nanoparticles useful in medicine
not found natural in body so can be easily targeted
give 2 examples of treatments targeting nanoparticles
photothermal therapy
radio sensitisation enhancement
describe advantages of INPs in theranostics
large surface area can be tailored
can contain disease site targeting carriers
what are the 3 types of INPs
crystalline solids
composite materials
macromolecular metal ion chelates
give examples of crystalline solid INPs
colloidal gold
silver NPs
how are composite material nanoparticles made and give an example
dope nanoparticles with other metals
Au/Si nanoshells
what is the main barrier to market for most INPs
metal ion toxicity
why is metal ion toxicity a problem
excess ions overrun body
nanoparticles do not show same properties as bulk
distribution is difficult to study
how can metal ion toxicity be overcome
put metal in stable chelate or form stable nanoparticle
what conditions in the body must a nanomedicine withstand
37 degrees pH 7.4
local low pH
competing background media
what are the 2 main considerations when selecting ligands for a nanoparticle
HSAB
shape of particle
what are 3 processes that render a nanoparticle ineffective in vivo
electrolytes can cause aggregation of charge stabilised NPs
proteins can cause aggregation or form protein corona
can be opsonized
what is opsonization
marking for phagocytes
what are the 3 different types of metal nanoparticles
noble metals (Au/Ag)
oxides
binary NPs
what are the advantages of steric stabilisation of nanoparticles
stealthy to immune system using PEG groups
resistant to salts
what effects does size of hydrodynamic radii have
small = better at avoiding opsonization large = greater stability
what effect do macromolecular chelates have on metal ions
changes biodistribution
changes targeting
reduces off target toxicity
what must you bare in mind regarding macromolecular chelate stability
CFSE, CN
how can kinetic inertness be promoted
choose stable oxidation state
high CN
how are metallic inorganic nanoparticles synthesised
salt with salt solution
nucleate - reduce ion
grows until stable size is formed
what is the role of stabilisers in nanoparticle growth
stops aggregation
can also act as reducing agents
how can nanoparticles be made to be stable in aqueous solution
either; synthesise in aqueous
synthesise in organic do ligand exchange to aqueous
what are the 2 methods of targeting tumours
passive (EPR)
active - via overexpressed receptors in tumours
describe the properties of colloidal gold
stable, generally non toxic
surface plasmon resonance wavelength depends on NP size shape and surrounding medium
describe the Turkevich-Frens method
add citrate to HAuCl4
solution changes colour as gold is reduced
citrate is stabiliser and reducing agent
size controlled by Au citrate ratio
how is uniformity achieved in turkevich frens
pH 5 and uniform stirring
what size particles are formed in turkovich frens
10-15 nm
how can larger particles be made with turkovich frens
add HAuCl4 to citrate
forms seeds
further addition of Au grows particles
how can smaller particles be made using turkovich frens
add HAuCl4 to citrate
add NaBH4 - becomes main reducing agent
high citrate conc inhibits particle growth